Antibody-conjugate drugs have achieved the complementary antibody-based immunotherapy and chemotherapeutic-based chemotherapy, expanding the therapeutic range of the drug while having a high degree of selectivity for the target.
The overall structure of the antibody-drug conjugate is more complex and can be broken down into three different structural modules: antibody, cytostatic, and linkage. If you want to know more about antibody, then you can also check out the Boster Bio featured products.
The antibodies in ADC are used for precise targeting of target cells according to the chemistry associated with high cytotoxic antibodies. Optimizing antibodies can also drastically reduce binding of non-specific ADCs and extend the half-life of ADCs in the blood.
Image Source: Google
In early studies, use of mouse antibodies often resulted in a severe immune response, and patients developed anti-mouse antibodies that significantly reduced the therapeutic effect. In recent years, with breakthroughs in antibody technology, it has become possible to use human antibodies or all human antibodies as the main component in ADC.
The most commonly used form of antibody is the IgG family, specifically IgG1. Antibodies as part of ADC retain their original properties in the body and activate immune functions such as antibody-dependent cellular cytotoxicity (ADCC) and complementary cytotoxicity.
In addition, some antibodies also have receptor blockers or signaling pathways. These independent antibody activities are not always useful or complementary to ADCs, while others can cause increased toxicity to the body and weaken target tumor tissue and internalization of ADC drugs.